News

The University of Bristol research team used animal models to compare patient responses to AAV therapy, studying male and female eye cells across different age groups (young, middle-aged and older patients)

The study underscored a need for tailored approaches among specific patient populations

How modern tools may lead to customized AMD treatment plans

The authors conducted a retrospective, cross-sectional study in which they described a technique for estimating the melanocytic choroidal tumor thickness using only Optomap UWF images.

The research team conducted a prospective study to assess any barriers to parental compliance with vision testing in preschoolers aged 3 to 6 years.

Researchers screened for outcomes such as the presence of retinal diseases including age-related macular degeneration and retinal vein occlusion

David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial.

The European Medicines Agency's new standard procedure allows manufacturers to request advice from medical device expert panels

Sara M. Thomasy, DVM, PhD, DACVO, discusses the importance of examining how glaucoma affects companion animals like dogs, cats and horses

Researchers from the University of Bristol recorded increased instances of inflammation in particular demographic groups

Researchers used data from the UK Biobank to investigate the associations between a healthy lifestyle score and retinal neurovascular health.

Mariya Moosajee, MBBS, BSc, PhD, FRCOphth, discusses how Gene Vision is improving patients' lives on a global scale

Routine evaluation of meibomian glands, starting in childhood, is crucial for identifying and managing this progressive disease before it leads to long-term ocular surface issues.

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long alternative to intravitreal injections.

According to the company, the suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and neuropathic pathways.

The interventional glaucoma mindset can maximise quality of life, but requires clinicians to act fast

The study’s main outcome measures were the changes in those 2 parameters following treatment with teprotumumab.

The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, rashes, and a chemical corneal burn in babies.

The trial will feature the company’s product candidate, AXV101, focused on combating childhood blindness due to retinitis pigmentosa (RP) caused by Bardet-Biedl Syndrome 1 (BBS1).

Yvonne Ou, MD, a professor of ophthalmology at the University of California San Francisco, spoke about lifestyle modifications for glaucoma at this year's Glaucoma 360 meeting.

Nathan Congdon, MD, highlights a recent study showing how virtual mentor-mentee relationships through Orbis' free telemedicine and e-learning platform can significantly enhance care.

The 2 phase II trials, Osprey and Apteryx successfully met all primary and secondary endpoints.

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib injectable suspension) in participants with neovascular age-related macular degeneration.

M. Roy Wilson, presented the Shaffer-Hetherington-Hoskins Lecture at the Glaucoma 360 meeting held in San Francisco, California. This lecture was entitled, "Rethinking Race as a Risk Factor for Glaucoma: What Really Matters?"

Ooms' poster at the Association of University Professors of Ophthalmology annual meeting highlighted a study on gray area complications in strabismus surgery, showing that trainees are more likely than attendings to disclose these complications despite having similar baseline anxiety levels. Ooms is a PGY-4 ophthalmology resident at the Dean McGee Eye Institute.